Praxis Precision Medicines Shares Double After Promising Phase 3 Tremor Trial Results

Praxis Precision Medicines shares doubled following positive topline results from pivotal Phase 3 studies of ulixacaltamide HCl for treating essential tremor, demonstrating statistical significance in clinical endpoints.

• In a parallel-group study (Study 1), patients treated with ulixacaltamide HCl achieved a mean improvement of 4.3 points in the Modified Activities of Daily Living 11 at Week 8, indicating statistical significance.
• The pivotal Phase 3 trials assessed the efficacy of ulixacaltamide HCl against a placebo, focusing on its effects on tremor associated with essential tremor.
• As a result of the promising trial results, Praxis Precision Medicines stock surged 100%, reflecting strong investor confidence in the treatments potential for managing essential tremor.